Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 2, 2003, Pages 556-562

  Zong, Jian ^a   Pollack, Gary M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; MORPHINE; QUINIDINE; RIFAMPICIN; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; BRAIN TISSUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG PENETRATION; INHIBITION KINETICS; LONG TERM EXPOSURE; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN TRANSPORT;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MICE; P-GLYCOPROTEIN; PERFUSION; QUINIDINE; RIFAMPIN; VERAPAMIL;

EID: 0038637177     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.049452     Document Type: Article

References (32)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1999) Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398.
2. Aquilante CL, Letrent SP, Pollack GM, and Brouwer KL (2000) Increased brain P-glycoprotein in morphine tolerant rats. Life Sci 66:PL47-PL51.
3. Bergwerk AJ, Shi X, Ford AC, Kanai N, Jacquemin E, Burk RD, Bai S, Novikoff PM, Stieger B, Meier PJ, et al. (1996) Immunologic distribution of an organic anion transport protein in rat liver and kidney. Am J Physiol 271:G231-G238.
4. 2,5]enkephalin in mdr1a-gene-deficient mice. J Pharmacol Exp Ther 287:545-552.
5. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, and Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
6. Dagenais C, Rousselle C, Pollack GM, and Scherrmann JM (2000) Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 20:381-386.
7. Dagenais C, Zong J, Ducharme J, and Pollack GM (2001) Effect of mdrla P-glycoprotein gene disruption, gender and substrate concentration on brain uptake of selected compounds. Pharm Res (NY) 18:957-963.
8. Demeule M, Jodoin J, Beaulieu E, Brossard M, and Beliveau R (1999) Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett 442:208-214.
9. Fardel O, Lecureur V, Loyer P, and Guillouzo A (1995) Rifampicin enhances anticancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmcol 49:1255-1260.
10. Fromm MF, Eckhardt K, Li S, Schanzle G, Hofmann U, Mikus G, and Eichelbaum M (1997) Loss of analgesic effect of morphine due to coadministration of rifampin. Pain 72:261-267.
11. Furusawa S, Nakano S, Wu J, Sasaki K, Takayanagi M, and Takayanagi Y (1997) Potentiation of pirarubucin activity in multidrug resistant cells by rifampicin. Biol Pharm Bull 20:1303-1306.
12. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
13. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, and Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Investig 104:147-153.
14. Hsu SI, Lothenstein L, and Horwitz SB (1989) Differential overexpression of three mdr gene family members in multidrug resistant J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes. J Biol Chem 264:12053-12062.
15. Hyafil F, Vergely C, Du Vignaud P, and Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602.
16. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
17. LeCluyse EL (2001) Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem Biol Interact 134:283-289.
18. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, and Dey S (1998) HIV-1 protease inhibitors are substrates for MDR1 multidrug transporter. Biochemistry 37:3594-3601.
19. Lemaire M, Bruelisauer A, Guntz P, and Sato H (1996) Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother Pharmacol 38:481-486.
20. Leveille-Webster CR and Arias IM (1995) The biology of the P-glycoproteins. J Membr Biol 143:89-102.
21. Lowry OH, Rosebough NJ, Farr AL, and Randal RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
22. Martin C, Berridge G, Higgins C, Mistry P, Charlton P, and Callaghan R (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624-632.
23. Prince C, Miller DW, Stemmer PM, Strong ML, Ueda CT, and Elmoquist WF (1996) The effect of chronic oral dosing cyclosporine A on the expression of P-glycoprotein in the rat. Pharm Res (NY) 13:S456.
24. Ruetz S and Gros P (1994) Phosphotidylcholine translocase: a physiological role for the mdr2 gene. Cell 77:1071-1081.
25. Schinkel AH (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8:161-170.
26. Schuetz EG, Beck WT, and Schuetz JD (1996) Modulators and substrates of P-lycoprotien and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
27. Shapiro AB, Fox K, Lam P, and Ling V (1999) Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 259:841-850.
28. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, and van Roon MA (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75:451-462.
29. Smith QR (1996) Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system, in Models for Assessing Drug Absorption and Metabolism (Borchardt RT, Smith PL, and Wilson G eds) pp 285-307, Plenum Press, New York.
30. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
31. Wang EJ, Casciano CN, Clement RP, and Johnson WW (2000) Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence. Biochim Biophys Acta 1481: 63-74.
32. Zong J and Pollack GM (2000) Morphine antinociception is enhanced in mdr1a Gene-deficient mice. Pharm Res (NY) 17:749-753.